Q2 2026 13F · SEC CIK 1637359
Omega Fund Management, LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $185.7M
- Reported positions
- 10
- Top holdings a year, 3 yrs
- -19.5%
- Assets under management
- $1.7B
Omega Fund Management, LLC is a hedge fund that reported 10 positions worth $185.7M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Bicara Therapeutics Inc (BCAX, 29.1%), Nuvation Bio Inc (NUVB, 24.7%), Kestra Med Technologies Ltd (KMTS, 14.0%). A portfolio copying its top holdings returned -19.5% a year over the last 3 years, against 17.1% for the S&P 500.
Omega Fund Management, LLC holdings all 10 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| BCAXBicara Therapeutics Inc | 29.1% | -23.8% | $54.1M |
| NUVBNuvation Bio Inc | 24.7% | +0.0% | $45.9M |
| KMTSKestra Med Technologies Ltd | 14.0% | +0.0% | $26.0M |
| BBOTBridgebio Oncology Therapeut | 13.5% | +0.0% | $25.1M |
| BBNXBeta Bionics Inc | 11.1% | +0.0% | $20.6M |
| ALMSAlumis Ord | 3.7% | +0.0% | $6.8M |
| SANASana Biotechnology Inc | 1.6% | +0.0% | $2.9M |
| IMAImagenebio Inc | 1.4% | +0.0% | $2.7M |
| ENGNenGene Holdings Inc. | 0.8% | +0.0% | $1.5M |
| ODTXOdyssey Therapeutics, Inc. | 0.0% | — | $54K |
What Omega Fund Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- ODTX Odyssey Therapeutics, Inc.0.0% of 13F
Added to
No position grew by more than 5%.
Reduced
- BCAX Bicara Therapeutics Inc-23.8% shares
Sold out
- REPL Replimune Group Incwas 1.2%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +60.6% /yr
- S&P 500 +20.1%
- 3 years
- -19.5% /yr
- S&P 500 +17.1%
- 5 years
- -22.8% /yr
- S&P 500 +9.7%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $185.7M | 10 |
| Q1 2026 | $163.1M | 10 |
| Q4 2025 | $286.5M | 11 |
| Q3 2025 | $222.4M | 12 |
| Q2 2025 | $154.4M | 13 |
| Q1 2025 | $169.5M | 13 |
| Q4 2024 | $120.7M | 11 |
| Q3 2024 | $160.0M | 11 |
| Q2 2024 | $135.0M | 11 |
| Q1 2024 | $155.0M | 11 |
| Q4 2023 | $123.4M | 14 |
| Q3 2023 | $108.9M | 12 |
Questions about Omega Fund Management, LLC's portfolio
What stocks does Omega Fund Management, LLC own?
Omega Fund Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 10 positions worth $185.7M. The largest are Bicara Therapeutics Inc (BCAX) at 29.1%, Nuvation Bio Inc (NUVB) at 24.7%, Kestra Med Technologies Ltd (KMTS) at 14.0%, Bridgebio Oncology Therapeut (BBOT) at 13.5% and Beta Bionics Inc (BBNX) at 11.1%.
What did Omega Fund Management, LLC buy last quarter?
In Q2 2026, Omega Fund Management, LLC added a new position in Odyssey Therapeutics, Inc. (ODTX), compared with its Q1 2026 filing.
What did Omega Fund Management, LLC sell last quarter?
In Q2 2026, Omega Fund Management, LLC sold all of Replimune Group Inc (REPL) and Bicara Therapeutics Inc (BCAX) (-23.8% shares), compared with its Q1 2026 filing.
How has Omega Fund Management, LLC's portfolio performed?
A portfolio copying Omega Fund Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned -19.5% a year over the last 3 years, against +17.1% for the S&P 500. Over 1 year: +60.6% against +20.1%. Over 5 years: -22.8% a year against +9.7%.
When is Omega Fund Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Omega Fund Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Omega Fund Management, LLC manage?
Omega Fund Management, LLC reported $1.7B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $185.7M.